Clinical Report: Metagenomic Analysis of Gut Microbiota in RA-ILD Patients

Overview

This study investigates the gut microbiota in patients with rheumatoid arthritis-associated interstitial lung disease (RA-ILD), revealing specific microbial alterations linked to systemic inflammation. Notably, Escherichia/Shigella was enriched, while Roseburia and Ruminococcus were depleted in RA-ILD patients compared to RA-non-ILD.

Background

Rheumatoid arthritis-associated interstitial lung disease (RA-ILD) represents a significant extra-articular complication of rheumatoid arthritis, with limited diagnostic biomarkers available. Understanding the role of gut microbiota dysbiosis in RA-ILD could provide insights into its pathogenesis and potential therapeutic targets. The gut-lung axis may play a crucial role in mediating inflammation and disease progression in RA-ILD.

Data Highlights

No significant differences in alpha and beta diversity were observed among the groups. However, exploratory analyses indicated significant microbial taxa differences, with Escherichia/Shigella enrichment in RA-ILD and depletion of Roseburia and Ruminococcus.

Key Findings

• RA-ILD patients exhibited an enrichment of Escherichia/Shigella (11.72% vs. 2.66%, P=0.003).
• Depletion of Roseburia was noted in RA-ILD patients (1.05% vs. 3.77%, P=0.005).
• Ruminococcus was also depleted in RA-ILD patients (5.98% vs. 7.85%, P=0.032).
• Pro-inflammatory genera correlated positively with disease activity, while butyrate-producing genera correlated negatively.
• Random forest classification identified specific taxa as discriminators between healthy controls and RA patients.

Clinical Implications

The identified gut microbiota alterations in RA-ILD patients suggest potential biomarkers for disease monitoring and therapeutic targets. Clinicians should consider the gut-lung axis when evaluating systemic inflammation in RA-ILD.

Conclusion

This study highlights the association between gut microbiota changes and RA-ILD, emphasizing the need for further research to validate these findings as potential biomarkers and therapeutic targets.

Related Resources & Content

1. Frontiers in Medicine, 2026 -- Oral microbiota alterations in radiographic axial spondyloarthritis
2. Frontiers in Medicine, 2026 -- Editorial: Deciphering the microbiome's role in the progression of interstitial lung diseases
3. Journal of Gastroenterology -- Endoscopic Brush Sample Analysis Reveals Mucosal Dysbiosis in Patients with Inflammatory Bowel Disease
4. Frontiers in Medicine, 2026 -- A machine learning-based classification model for interstitial lung disease in rheumatoid arthritis
5. ERS/EULAR clinical practice guidelines for connective tissue disease-associated interstitial lung disease | European Respiratory Society
6. Nintedanib in Progressive Fibrosing Interstitial Lung Diseases | New England Journal of Medicine
7. ERS/EULAR clinical practice guidelines for connective tissue disease-associated interstitial lung disease | European Respiratory Society
8. Nintedanib in Progressive Fibrosing Interstitial Lung Diseases | New England Journal of Medicine